Akebia Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Akebia Therapeutics generated cash of -$23,384,000, which is more than the previous year. Cash used in financing activities reached the amount of -$25,206,000 last year. Net change in cash is therefore -$48,590,000.
Cash Flow
| 2014 | -27.48M | -65.35M | 104.4M |
|---|---|---|---|
| 2015 | -52.40M | -13.68M | 83.09M |
| 2016 | 57.90M | 12.70M | 66.94M |
| 2017 | -56.15M | -177.26M | 116.24M |
| 2018 | -97.49M | 36.59M | 96.56M |
| 2019 | -257.44M | 211.17M | 88.97M |
| 2020 | -110.38M | -40.00M | 231.72M |
| 2021 | -252.96M | 39.94M | 133.73M |
| 2022 | -73.15M | -114K | 14.59M |
| 2023 | -23.38M | 0 | -25.20M |
AKBA Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 93.16M | 151.83M | 231.13M | 149.80M | 107.09M | 71.43M | 187.33M | 49.77M | 32.78M | 21.21M |
Operating activities | ||||||||||
Net income | -51.92M | -92.56M | -282.84M | -383.45M | -279.65M | -143.58M | -76.91M | -135.74M | -60.71M | -37.03M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 41.84M | 37.69M | 37.97M | 33.59M | 38.64M | 2.42M | 617K | 296K | 96K | 49K |
Stock-based compensation expense | 9.31M | 17.84M | 22.73M | 24.46M | 11.92M | 0 | 8.86M | 5.82M | 4.71M | 6.01M |
| Deferred income tax benefit | 9.31M | 17.84M | 22.73M | 24.46M | 11.92M | 0 | 8.86M | 5.82M | 4.71M | 6.01M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 994K | 11.69M | -24.02M | 12.01M | -22.19M | 33.38M | -393K | -33.82M | 0 | 87K |
Inventories | -2.54M | 19.79M | -25.84M | 6.16M | -29.14M | 26K | 16.79M | 0 | 0 | -773K |
Accounts payable | -5.24M | 1.50M | -11.73M | 3.67M | 1.37M | 13.71M | 4.95M | -274K | 231K | 4.06M |
Cash generated by operating activities | -23.38M | -73.15M | -252.96M | -110.38M | -257.44M | -97.49M | -56.15M | 57.90M | -52.40M | -27.48M |
Investing activities | ||||||||||
Purchases Of Investments | 0 | 0 | 0 | -99.93M | 0 | -224.21M | -330.63M | -147.00M | -77.17M | -77.70M |
Investments In Property Plant And Equipment | 0 | -114K | -59K | -317K | -6.65M | -1.60M | -1.62M | -2.66M | -414K | -229K |
Acquisitions Net | 0 | 0 | 0 | 39.68M | 0 | 6.14M | 1.62M | 2.66M | 414K | 229K |
Cash generated by investing activities | 0 | -114K | 39.94M | -40.00M | 211.17M | 36.59M | -177.26M | 12.70M | -13.68M | -65.35M |
Financing activities | ||||||||||
Common Stock Issued | 6.79M | 7.53M | 88.20M | 209.41M | 26.16M | 0 | 114.93M | 66.73M | 82.97M | 104.32M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | -426K | 0 | 0 | 0 | 0 | -162K |
Repayments of term debt | -32M | -33M | -44.78M | -19.97M | 62.66M | -19K | -5K | -20K | -7K | -3K |
Cash used in financing activities | -25.20M | 14.59M | 133.73M | 231.72M | 88.97M | 96.56M | 116.24M | 66.94M | 83.09M | 104.4M |
Net Change In Cash | -48.59M | -58.67M | -79.29M | 81.32M | 42.70M | 35.66M | -117.17M | 137.55M | 16.99M | 11.56M |
Cash at end of period | 44.57M | 93.16M | 151.83M | 231.13M | 149.80M | 107.09M | 70.15M | 187.33M | 49.77M | 32.78M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |